Fairvalue-Calculator Fairvalue-Calculator
EN DE

NatureWise Biotech & Medicals Corporation (4732) Fair Value & Analysis

Healthcare · TW · Market cap 874M TWD

Price18.05 TWD
Fair Value2.04 TWD
Upside-88.7%
Quality92/100
Evidence: Low Range 1.76 TWD – 2.35 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

NatureWise Biotech & Medicals Corporation (4732) currently trades at 18.05 TWD, while our model-based Fair Value estimate is 2.04 TWD — implying the stock looks roughly 88.7% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is NatureWise Biotech & Medicals Corporation (4732) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 2.04 TWD versus a price of 18.05 TWD — about −89% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4732?
Our 21-model fair value for NatureWise Biotech & Medicals Corporation is 2.04 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 18.05 TWD.
What is the quality score of 4732?
NatureWise Biotech & Medicals Corporation has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.